United Therapeutic
(NQ:
UTHR
)
320.99
-2.09 (-0.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about United Therapeutic
< Previous
1
2
3
4
5
6
7
8
Next >
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis
October 11, 2022
From
United Therapeutics Corporation
Via
Business Wire
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market
October 05, 2022
Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks.
Via
InvestorPlace
United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease
September 20, 2022
Via
Benzinga
United Therapeutics Releases Its Annual Corporate Responsibility Report and Inaugural Public Benefit Report
September 12, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics: Return On Capital Employed Overview
August 08, 2022
Via
Benzinga
United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation
August 31, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics to Feature Clinical Data at the European Society of Cardiology Congress 2022 and the European Respiratory Society International Congress 2022
August 24, 2022
From
United Therapeutics Corporation
Via
Business Wire
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
August 10, 2022
Via
Investor Brand Network
Exposures
Product Safety
Expert Ratings for United Therapeutics
May 24, 2022
Within the last quarter, United Therapeutics (NASDAQ:UTHR) has observed the following analyst ratings:
Via
Benzinga
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
August 10, 2022
NetworkNewsWire Editorial Coverage New York, NY – August 10, 2022 – In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill...
Via
FinancialNewsMedia
Exposures
Product Safety
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
August 05, 2022
The Nasdaq and small caps rose while the S&P 500 is hitting resistance.
Via
Investor's Business Daily
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
August 03, 2022
From
United Therapeutics Corporation
Via
Business Wire
Earnings Outlook For United Therapeutics
August 02, 2022
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that United...
Via
Benzinga
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022
July 27, 2022
From
United Therapeutics Corporation
Via
Business Wire
7 Best Pharmaceutical Stocks to Buy Now
July 20, 2022
These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.
Via
InvestorPlace
Swing Trading Stock Watchlist For The Week Of July 11 And Beyond
July 09, 2022
The stock market's health is improving, but a likely bottom has not been confirmed yet. That means I’m buying some stocks (swing trades), but I'm not loading up yet. Let's see what I'm looking at.
Via
Talk Markets
7 Biotech Stocks With Key Catalysts Coming in July
June 27, 2022
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth.
Via
InvestorPlace
Buy These 3 Low-Beta Stocks To Sail Through A Choppy Market
June 25, 2022
Creating a portfolio of low-beta stocks is of utmost importance since the securities will deliver healthy returns and provide a shield against volatile market conditions.
Via
Talk Markets
Corcept Stock Near Buy Point; Strength Rating Jumps To 91
June 23, 2022
The new 91 RS Rating means that Corcept stock has outperformed 90% of all other stocks over the past year.
Via
Investor's Business Daily
Will Investors Notice Exciting Sign On United Therapeutics's Chart?
June 10, 2022
If history is any guide, there may be good fortune ahead for shares of United Therapeutics (NASDAQ:UTHR). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish...
Via
Benzinga
United Therapeutics Provides an Update on Its Organ Printing Programs
June 06, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
June 03, 2022
From
United Therapeutics Corporation
Via
Business Wire
Short Volatility Alert: United Therapeutics Corporation
May 26, 2022
On Wednesday, shares of United Therapeutics Corporation (NASDAQ: UTHR) experienced volatile short activity. After the activity, the stock price went up 4.31% to $228.39. The...
Via
Benzinga
United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot'
May 24, 2022
United Therapeutics stock had its Relative Strength (RS) Rating upgraded to 89 Tuesday, from 71 a day earlier.
Via
Investor's Business Daily
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
May 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
United Therapeutics Announces FDA Approval of Tyvaso DPI™
May 24, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics's Return on Invested Capital Insights
May 18, 2022
According to Benzinga Pro, during Q1, United Therapeutics (NASDAQ:UTHR) earned $239.90 million, a 113.81% increase from the preceding quarter. United Therapeutics also posted a total of $461.90 million...
Via
Benzinga
7 Biotech Stocks With Key Catalysts for May
May 11, 2022
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.
Via
InvestorPlace
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.